News Headlines

  1. Commencement Of BNC210 Phase 2 Clinical Trial For The Treatment Of Agitation
    5/23/2018

    Bionomics Limited, a global, clinical stage biopharmaceutical company, recently announces that a Phase 2 clinical trial of its therapeutic candidate, BNC210, has commenced in elderly patients with agitation in the hospital setting. The first participant has been recruited into the trial.

  2. Major Cancer Center Further Advances Oncology Research By Integrating Genomic Data Into Medidata's eClinical Platform
    5/23/2018

    Medidata announced that Memorial Sloan Kettering Cancer Center (MSK) is using Rave Omics with Biomarker Discovery for patients with pancreatic cancer, an example of the paradigm shift in clinical trials through the systematic capture of genomic data and the application of artificial intelligence algorithms.

  3. WCG (WIRB-Copernicus Group) Clinical Services Division Opens Office In Japan
    5/22/2018

    WCG™ (WIRB-Copernicus Group®) Clinical Services Division, the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research, recently announced the opening of the company’s new office in Tokyo, Japan.

  4. Nabriva Therapeutics Announces Positive Topline Results From Pivotal Phase 3 Clinical Trial Of Oral Lefamulin For The Treatment Of Community-Acquired Bacterial Pneumonia
    5/21/2018

    Nabriva Therapeutics plc (NASDAQ:NBRV) today announced positive topline results from its Lefamulin Evaluation Against Pneumonia (LEAP 2) clinical trial, the second of two global, pivotal Phase 3 clinical trials of lefamulin.

  5. MimiVax Announces Positive Interim Results From Phase II Trial Of SurVaxM Immunotherapy For The Treatment Of Newly Diagnosed Glioblastoma
    5/21/2018

    MimiVax LLC, a clinical-stage biotechnology company developing immunotherapeutics and targeted therapies for cancer treatment, today announced positive interim results from a multicenter Phase II study of SurVaxM in patients with newly diagnosed glioblastoma (nGBM).

  6. Beta Bionics Receives IDE Approval From The FDA To Begin A Home-Use Clinical Trial Testing The New iLet™ Bionic Pancreas System
    5/21/2018

    Beta Bionics, Inc. – a medical technology company leveraging machine learning artificial intelligence to develop and commercialize the world’s first autonomous bionic pancreas – today announced that it has received FDA approval to begin recruitment for home-use studies testing the insulin-only configuration of its iLet bionic pancreas system in a series of groundbreaking trials in adults and children with type 1 diabetes (T1D).

  7. uniQure Presents New Data Demonstrating Clinical Benefit In Hemophilia B Patients With Pre-Existing Anti-AAV5 Neutralizing Antibodies
    5/21/2018

    uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, presented data showing successful liver transduction with the AAV5 vector in both non-human primates and humans with pre-existing anti-AAV5 neutralizing antibodies (NABs).

  8. Recognition For CRF Health’s World Class eSource Wins European Award
    5/21/2018

    CRF Health, a leading global provider of patient-centered eSource technology solutions for the life sciences industry, recently announced that the company has been recognized as 2018 New Entrant of the Year in Romania’s Regional IT & Outsourcing Industry Awards, (also known as the PIN Awards).

  9. First Oral Insulin For Diabetics Takes Major Step Towards FDA Approval
    5/18/2018

    Oral insulin, the Holy Grail of diabetes care that has alluded researchers for decades, is taking a major step towards becoming reality.

  10. H2020, GDPR, MDR And International Clinical Trial Regulation Blockchain Integrates CRO Solution From ClinicalStudio.EU To Manage Compliance With Smartillions Smart Contracts
    5/18/2018

    Clinical research organisations (CRO) and sponsors who sign up for ClinicalStudio.EU will be able to use a blockchain to launch Smartillions smart contracts to manage their Horizon 2020 R&D grant applications and compliance with GDPR, MDR and international clinical trial regulations.